ABVC BioPharma(ABVC) - 2025 Q2 - Quarterly Results

FORM 8-K Filing Information This section outlines the registrant's legal name, filing date, contact details, and emerging growth company status Registrant and Filing Details This section provides the registrant's legal name, jurisdiction, contact information, filing date, and emerging growth company status - Company Name: ABVC BIOPHARMA, INC.[1] - Date of Report (Earliest Event): August 14, 2025[1] Registrant Contact and Incorporation Details | Detail | Value | | :--- | :--- | | State or other jurisdiction of incorporation | Nevada | | Commission File Number | 001-40700 | | IRS Employer Identification No. | 26-0014658 | | Address of principal executive offices | 44370 Old Warm Springs Blvd., Fremont, CA 94538 | | Registrant's telephone number | (510) 668-0881 | - The registrant is not an emerging growth company[3] Securities Information This section details the company's registered securities under Section 12(b), including stock class, trading symbol, and exchange Registered Securities Details | Title of Each Class | Trading Symbol | Name of each exchange on which registered | | :------------------ | :------------- | :---------------------------------------- | | Common Stock, par value $0.001 per share | ABVC | The Nasdaq Stock Market LLC | Item 2.02 Results of Operations and Financial Condition This item reports the announcement of financial results for the second quarter and includes a disclaimer regarding securities offerings Announcement of Financial Results ABVC BioPharma, Inc. announced Q2 2025 financial results via press release, furnished but not filed, limiting liability - ABVC BioPharma, Inc. issued a press release on August 14, 2025, announcing financial results for Q2 ended June 30, 2025[4] - The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K[4] - This information is furnished, not filed, under Section 18 of the Securities Exchange Act of 1934, and is not incorporated by reference unless explicitly stated[5] Disclaimer Regarding Securities Offerings This section disclaims that the Form 8-K constitutes an offer to sell or solicit securities, noting they are unregistered under the Securities Act of 1933 - This Form 8-K and its exhibits do not constitute an offer to sell or a solicitation to buy the described securities[6] - The securities are unregistered under the Securities Act of 1933 and require registration or an applicable exemption for U.S. offers or sales[6] Item 9.01 Exhibits This item provides a comprehensive list of all exhibits furnished with the Form 8-K filing List of Exhibits This section lists all exhibits furnished with the Form 8-K, including their exhibit number and description Form 8-K Exhibits | No. | Description | | :-- | :---------- | | 99.1 | Press Release | | 104 | Cover Page Interactive Data File, formatted in Inline XBRL | Signature This section formally concludes the report with the authorized signatory's details and date Authorized Signatory This section formally concludes the report, confirming its due signing by an authorized officer of ABVC BioPharma, Inc - The report was signed on August 14, 2025, by Uttam Patil, Chief Executive Officer of ABVC BioPharma, Inc.[9][10][11]